周五(5月2日)盘中，生物技术公司Arvinas(ARVN)股价大跌5.12%，引发市场关注。
消息面上，多家知名券商大幅下调了Arvinas的目标股价。其中，杰富瑞将Arvinas的评级从"买入"下调至"持有"，目标价从52美元大幅下调至10美元。BTIG也将目标价从69美元下调至16美元，Piper Sandler将目标价从24美元下调至14美元。此外，巴克莱和古根海姆也均将目标价下调至16美元。
分析人士认为，如此多的机构大幅下调Arvinas的目标价，暗示该公司可能面临重大不利因素或业务前景恶化。虽然目前尚不清楚具体原因，但投资者对此反应强烈，导致股价大幅下挫。市场将密切关注Arvinas未来的业务进展和财报表现，以评估公司的长期发展前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.